Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 20 December 1996:
Vol. 274. no. 5295, pp. 2004 - 2005
DOI: 10.1126/science.274.5295.2004
Prev | Table of Contents | Next

News & Comment

Martin Enserink

Amsterdam, the Netherlands--The Second European Stroke Prevention Study, a major clinical trial of a drug to prevent repeat strokes, has become mired in controversy. A paper describing promising results from the trial, published earlier this month, was originally turned down by The Lancet in part because of ethical concerns over the use of placebos, and it has been further tainted by allegations that fabricated data led to the disqualification of information on more than 400 patients.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Dipyridamole Plus Aspirin in Cerebrovascular Disease.
S. N. Cohen, J. D. Easton, and J. L. Wilterdink (2000)
Arch Neurol 57, 1086-1087
   Full Text »    PDF »
Supplement to the AHA Guidelines for the Management of Transient Ischemic Attacks • Response to Dr Hughes:.
R. L. Hughes, G. W. Albers, R. G. Hart, H. L. Lutsep, D. W. Newell, and R. L. Sacco (2000)
Stroke 31 , 983-991
   Full Text »
Dipyridamole Plus Aspirin in Cerebrovascular Disease.
J. L. Wilterdink and J. D. Easton (1999)
Arch Neurol 56, 1087-1092
   Abstract »    Full Text »    PDF »
Evidence based cardiology: Prevention of ischaemic stroke.
H. J M Barnett, M. Eliasziw, and H. E Meldrum (1999)
BMJ 318, 1539-1543
   Full Text »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)